The Mesoridazine Test is a specialized diagnostic procedure offered at DNA Labs UAE, designed to monitor and measure the levels of mesoridazine in a patient's blood. Mesoridazine, an antipsychotic medication used for the treatment of schizophrenia and other mental health disorders, requires careful dosage management to ensure therapeutic effectiveness while minimizing potential side effects. The test plays a crucial role in the therapeutic drug monitoring (TDM) of patients on mesoridazine, aiding healthcare providers in adjusting dosages for optimal outcomes.
Conducted in the state-of-the-art facilities of DNA Labs UAE, the test ensures accuracy and reliability in results, thanks to the lab's adherence to stringent quality standards. The cost of the Mesoridazine Test is set at 1900 AED, reflecting the comprehensive approach taken in the analysis, including the use of advanced technology and the expertise of skilled professionals in the field. This test is particularly important for patients undergoing treatment with mesoridazine, as it helps in preventing underdosing or overdosing, thereby contributing to more effective and safer treatment protocols.
The "AML Categorization PCR Test" is a specialized diagnostic procedure offered by DNA Labs UAE, designed to identify specific genetic mutations associated with Acute Myeloid Leukemia (AML). By utilizing the Polymerase Chain Reaction (PCR) technology, this test amplifies and examines segments of DNA to pinpoint mutations that can influence treatment decisions and prognosis for AML patients. The cost of the test is set at 1900 AED, making it a valuable tool for both patients and healthcare providers in the United Arab Emirates for the effective management and treatment of AML. This precise and targeted approach aids in categorizing the type of AML, enabling personalized treatment plans that can significantly improve patient outcomes.
The CA 27.29 and CA 15.3 Breast Cancer Markers Panel Test is a crucial diagnostic tool used in the monitoring and management of individuals with breast cancer. This test measures the levels of two tumor markers, CA 27.29 and CA 15.3, which are substances often found in higher concentrations in the blood of individuals who have breast cancer. These markers can be elevated in the presence of breast cancer and may indicate the progression or recurrence of the disease.
The test is conducted at DNA Labs UAE, a reputable facility known for its advanced diagnostic services. The cost of the CA 27.29 and CA 15.3 Breast Cancer Markers Panel Test at DNA Labs UAE is 1870 AED. This test is particularly valuable for those undergoing treatment for breast cancer, as it helps healthcare providers assess the effectiveness of treatment and monitor for any signs of cancer recurrence. It is important to note that while this test can provide critical information about breast cancer status, it is typically used in conjunction with other diagnostic methods for a comprehensive evaluation.
Chimerism Split Cell Analysis, specifically the B Cell CD19 Test, is an advanced diagnostic procedure available at DNA Labs UAE, designed to monitor chimerism levels in patients who have undergone hematopoietic stem cell transplantation (HSCT). This test focuses on the CD19 marker, a protein expressed on the surface of B cells, which are a type of white blood cell crucial for the immune response. By analyzing the proportion of donor and recipient cells in the patient's blood, the B Cell CD19 Test provides valuable insights into the success of the transplantation, the risk of graft-versus-host disease (GVHD), and the patient's overall immune reconstitution.
The test is priced at 1870 AED and is conducted in the state-of-the-art facilities of DNA Labs UAE, which is known for its cutting-edge technology and highly qualified staff. This specific analysis is vital for post-transplant care, allowing healthcare providers to tailor treatment plans effectively and monitor patients' progress closely.
Chimerism Split Cell Analysis, specifically focusing on Myeloid Cell CD15 testing, is a specialized diagnostic procedure aimed at identifying the presence of two or more genetically distinct cell populations within an individual, often as a result of bone marrow or stem cell transplantation. This test is particularly critical in monitoring and assessing the success of transplant procedures, ensuring that the donor cells are effectively engrafting and replacing the recipient's original cells.
The CD15 marker is predominantly found on the surface of myeloid cells, which include neutrophils, eosinophils, and monocytes - key components of the immune system. By analyzing these cells for chimerism, medical professionals can gain valuable insights into the patient's post-transplant recovery process, including the detection of potential graft-versus-host disease (GVHD) or graft rejection early on.
Conducted at DNA Labs UAE, this test is meticulously designed to provide accurate and crucial information regarding the engraftment status and immune system health post-transplant. The cost of the Myeloid Cell CD15 Test is set at 1870 AED, reflecting the sophisticated nature of the analysis and the invaluable data it offers in guiding patient care and treatment plans.
Chimerism Split Cell Analysis, particularly focusing on the T Cell CD3 Test, is a sophisticated diagnostic procedure available at DNA Labs UAE. This test, costing 1870 AED, is designed to assess the presence and extent of chimerism in individuals who have undergone allogeneic stem cell transplantation. By isolating and analyzing T cells, specifically looking at the CD3 marker—a core component of the T-cell receptor complex on T lymphocytes—this test provides critical insights into the patient's immune system status and the success of the stem cell transplant.
The procedure is crucial for monitoring and managing post-transplant patients, as it helps in identifying graft-versus-host disease (GVHD) risks, guiding immunosuppressive therapy, and detecting potential transplant rejection early. Conducted in the state-of-the-art facilities of DNA Labs UAE, this test leverages advanced molecular techniques to deliver precise and reliable results, playing a vital role in the post-transplant care and overall patient management strategy.
The CK CPK Isoenzyme Electrophoresis Test is a specialized diagnostic procedure aimed at analyzing the specific isoenzymes of Creatine Kinase (CK) or Creatine Phosphokinase (CPK) present in the blood. This test is particularly significant in identifying and evaluating various muscle and heart conditions, as CK/CPK enzymes are released into the bloodstream following muscle or heart tissue damage. By distinguishing between the different isoenzymes, healthcare providers can pinpoint the source of muscle damage, whether it be cardiac, skeletal, or due to other causes, facilitating accurate diagnosis and tailored treatment plans.
Performed at DNA Labs UAE, a state-of-the-art facility known for its advanced diagnostic services, the CK CPK Isoenzyme Electrophoresis Test is available for a cost of 1870 AED. The lab ensures precise and reliable results, utilizing the latest in electrophoresis technology to separate and identify the specific isoenzymes of CK/CPK. This test is instrumental for patients experiencing symptoms of muscle weakness, pain, or those who have suffered a heart attack, as it aids in assessing the extent of muscle damage and monitoring recovery. With its commitment to quality healthcare and diagnostic excellence, DNA Labs UAE provides a crucial service in the management of conditions affecting the heart and muscles.
The "FISH - RET Gene 10q11.2 Rearrangement Test" is a specialized diagnostic tool used to detect rearrangements in the RET gene located on chromosome 10q11.2. This test is particularly important in the study and management of certain types of cancers, including medullary thyroid carcinoma and other tumors associated with the RET proto-oncogene. The test employs Fluorescence In Situ Hybridization (FISH) technology, which allows for the visualization of specific genetic material in the cells. This technique can identify chromosomal abnormalities, including translocations and inversions, that might not be detectable with other testing methods. Conducted at DNA Labs UAE, a leading facility in genetic testing, the test is priced at 1870 AED. This facility ensures precise and reliable results, providing essential information for the diagnosis, prognosis, and treatment planning for patients with conditions related to RET gene rearrangements.
The Growth Disorder Panel Test, available at DNA Labs UAE for a cost of 1870 AED, is a comprehensive diagnostic tool designed to identify genetic factors contributing to various growth disorders. This specialized test examines a range of genetic markers associated with conditions that affect growth patterns, such as dwarfism, gigantism, and other growth hormone irregularities. By analyzing specific DNA sequences, the panel helps in pinpointing genetic mutations or abnormalities that may be influencing an individual's growth development. The results from this test can provide crucial insights for healthcare providers, enabling them to devise personalized treatment plans or interventions to address these growth disorders effectively. DNA Labs UAE, with its state-of-the-art facilities and expert team, ensures precise and reliable testing outcomes, making it a preferred choice for individuals seeking answers to growth-related concerns.
The HLA Mixed Antibody Screen - PRA (Panel Reactive Antibody) Class I, II, and MICA Test is a sophisticated diagnostic assessment designed to evaluate the presence of antibodies against human leukocyte antigens (HLA) and Major Histocompatibility Complex class I chain-related gene A (MICA) in the bloodstream. This test is crucial for individuals undergoing or planning to undergo organ transplantation, as the presence of these antibodies can significantly affect the compatibility between donor and recipient, potentially leading to transplant rejection.
The test specifically screens for antibodies against HLA Class I and Class II antigens, which are critical for immune response and organ transplant compatibility. Additionally, it assesses antibodies against MICA, which have been associated with transplant rejection and reduced graft survival. By identifying these antibodies, healthcare providers can better match donors and recipients, minimize the risk of rejection, and improve transplant outcomes.
Performed at DNA Labs UAE, a leading diagnostic and research facility, the test is executed with precision and accuracy, ensuring reliable results for patients and healthcare professionals. The cost of the HLA Mixed Antibody Screen - PRA Class I, II, and MICA Test is 1870 AED, reflecting the comprehensive and detailed analysis involved in this assessment.
This test represents a critical step in pre-transplant evaluation, helping to ensure the highest levels of compatibility and success in organ transplantation procedures.
